NRXS

Neuraxis, Inc. (NRXS) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Neuraxis, Inc. is a growth-stage medical device company focused on neuromodulation therapies. Its primary revenue-generating product is the IB-STIM, a percutaneous electrical nerve field stimulator for pediatric functional abdominal pain. The company also markets the RED device for rectal expulsion evaluation and holds licenses for the NSS-2 Bridge (marketed by Masimo). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 38.5% to $895,655, driven by volume growth from customers with full insurance reimbursement and participation in patient financial assistance programs.
• Margin Compression: Gross margin decreased to 84.4% from 88.4% due to a higher mix of discounted sales through financial assistance programs and increased manufacturing/shipping costs.
• Expense Increases:
  • General & Administrative (G&A): Increased 23.2% to $2.86M, primarily due to a $619,097 charge for a tentative litigation settlement, new incentive plans, and higher advertising costs.
  • R&D: Increased 987.2% to $60,556 due to spending on medical research projects and RED device development.
  • Selling Expenses: Increased 67.4% to $133,954 due to higher sales volume and temporary commission structures.
• Other Income/Expense: Improved significantly to a net income of $16,414 (from a $288,531 expense in Q1 2024) due to the absence of financing charges and the conversion of convertible notes to Series B Preferred Stock, eliminating related interest and amortization costs.
• Liquidity: Cash decreased by $1.69M during the quarter due to operating losses. However, cash balances remain significantly higher than the prior year period ($2.0M vs $81k).

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Future operations depend on securing insurance coverage adoption and raising additional capital.
• Litigation Settlement: A tentative settlement of $750,000 was reached on April 25, 2025, regarding a lawsuit involving allegations of misrepresentation regarding Medicare billing. The company recorded a $619,097 charge in Q1 2025. Payments are scheduled to begin in January 2026.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including ineffective approval processes, inadequate contract management, and misapplication of U.S. GAAP. Remediation efforts are ongoing.
• Preferred Stock: The company has 4,280,939 shares of Series B Preferred Stock outstanding with cumulative dividends of 8.5% per annum. Undeclared dividends totaled $424,811 as of March 31, 2025.
• Outlook: The primary driver for future revenue is the adoption of insurance coverage by commercial carriers. The company expects to incur significant operating losses in the foreseeable future.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $2.0M cash balance given the $1.6M operating cash burn in Q1 and the "substantial doubt" going concern warning.
• Litigation Impact: Confirm the final terms of the $750,000 settlement and the impact of the remaining $130,903 (difference between settlement and recorded charge) on future periods.
• Insurance Adoption: Assess the progress of insurance carrier adoption for the IB-STIM device, which management cites as the critical factor for profitability.
• Internal Control Remediation: Monitor the timeline and success of remediation efforts for the identified material weaknesses in financial reporting.
• Preferred Stock Dilution: Review the terms of the Series B Preferred Stock, including the 8.5% cumulative dividend obligation and conversion rights, to understand potential dilution to common shareholders.